Healthcare Costs and Workloss Burden of Patients with Chemotherapy-Associated Peripheral Neuropathy in Breast, Ovarian, Head and Neck, and Nonsmall Cell Lung Cancer

Table 4

Chemotherapy agents and comorbidities of CAPN cases and non-CAPN controls during the 12-month study period.

	(A) Main Sample: no diabetes					(B) Diabetes Sample
	Cases		Controls		𝑃-value^a	Cases		Controls		𝑃-value^a
	No.	%	No.	%		No.	%	No.	%
𝑁	454		454			71		71
Metastatic cancer	171	38%	136	30%	0.0097	30	42%	22	31%	0.1306
Classes of select chemotherapy agents used
Taxanes	148	33%	125	28%	0.0978	30	42%	17	24%	0.0236
Vinca Alkaloids	18	4%	14	3%	0.4497	3	4%	2	3%	0.6547
Platinums	90	20%	80	18%	0.4014	17	24%	20	28%	0.5775
Comorbidities
Depressive disorders	68	15%	50	11%	0.0804	8	11%	3	4%	0.1317
Congestive heart failure	23	5%	20	4%	0.6219	12	17%	12	17%	1.0000
Fibromyalgia	37	8%	8	2%	<.0001	8	11%	1	1%	0.0196
Obesity	9	2%	2	0%	<.0001	1	1%	0	0%	0.2568
Hypertension—uncomplicated	114	25%	83	18%	0.0134	33	46%	35	49%	0.7576
Hypertension—complicated	13	3%	13	3%	1.0000	5	7%	1	1%	0.1025
Other cancers^b	124	27%	101	22%	0.0838	20	28%	19	27%	0.8415
Charlson Comorbidity Index	4.7		4.1		<.0001	7.0		5.6		0.0052

CAPN indicates chemotherapy-associated peripheral neuropathy.
^a𝑃-values are determined using McNemar tests for proportions and paired 𝑡-tests for continuous measures.
^bOther cancers include all cancers other than head and neck, breast, non-small cell lung, and ovarian.